Business Context and Reporting Period
Company: Biocardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2026
Event: Regulation FD Disclosure regarding the oral presentation of preliminary results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) at the Euro PCR conference in Paris.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details the presentation of preliminary open-label cohort results for the CardiAMP CMI trial. Key clinical outcomes reported include:
- Safety: The minimally invasive procedure was well tolerated with no treatment-emergent major adverse cardiac events.
- Exercise Tolerance: Patients demonstrated an average increase of 179 seconds, a benefit that persisted through the two-year follow-up period.
- Angina Reduction: Frequency of angina episodes was reduced by an average of 82% at six months post-treatment.
- Patient Profile: All patients were on guideline-directed medical therapy and had exhausted available percutaneous and/or surgical options prior to treatment.
Guidance, Outlook, and Risks
Management Commentary: The results were presented by Dr. Amish Raval on behalf of the CardiAMP CMI Investigators, highlighting positive clinical outcomes up to two years of follow-up.
Legal Disclaimer: The information furnished under Item 7.01 and the attached press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard nature of clinical trial data, which remains preliminary.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical data and study limitations.
- Confirm the status of the full study population and whether these results represent the final analysis or an interim open-label cohort.
- Review subsequent filings for any updates on regulatory strategy or commercialization plans following these results.
- Check the company's most recent 10-K or 10-Q for current financial liquidity and cash runway, as this 8-K contains no financial data.